PT - JOURNAL ARTICLE AU - Bi, Qifang AU - Hong, Chengcheng AU - Meng, Juan AU - Wu, Zhenke AU - Zhou, Pengzheng AU - Ye, Chenfei AU - Sun, Binbin AU - Kucirka, Lauren M. AU - Azman, Andrew S. AU - Wang, Tong AU - Chen, Jiancong AU - Wang, Zhaoqin AU - Liu, Lei AU - Lessler, Justin AU - Edwards, Jessie K. AU - Ma, Ting AU - Zhang, Guoliang TI - Characterization of clinical progression of COVID-19 patients in Shenzhen, China AID - 10.1101/2020.04.22.20076190 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.22.20076190 4099 - http://medrxiv.org/content/early/2020/04/27/2020.04.22.20076190.short 4100 - http://medrxiv.org/content/early/2020/04/27/2020.04.22.20076190.full AB - The COVID-19 pandemic has stressed healthcare care systems throughout the world. Understanding clinical progression of cases is a key public health priority that informs optimal resource allocation during an emergency. Using data from Shenzhen, China, where all cases were monitored in hospital and symptom profiles and clinical and lab results were available starting from early stages of clinical course, we characterized clinical progression of COVID-19 cases and determined important predictors for faster clinical progression to key clinical events and longer use of medical resources. Epidemiological, demographic, laboratory, clinical, and outcome data were extracted from electronic medical records. We found that those who progressed to the severe stage, developed acute respiratory distress syndrome, and were admitted to the intensive care unit (ICU) progressed on average 9.5 days (95%CI 8.7,10.3), 11.0 days (95%CI 9.7,12.3), and 10.5 days (95%CI 8.2,13.3) after symptom onset, respectively. We estimated that patients who were admitted to ICUs remained there for an average of 34.4 days (95%CI 24.1,43.2) and the average time on a ventilator was 28.5 days (95%CI 20.0,39.1) among those requiring mechanical ventilation. The median length of hospital stay was 21.3 days (95%CI, 20.5, 22.2) for the mild or moderate cases who did not progress to the severe stage, but increased to 52.1 days (95%CI, 43.3, 59.5) for those who required ICU admission. Clear characterization of clinical progression informs planning for healthcare resource allocation during COVID-19 outbreaks and provides a basis that helps assess the effectiveness of new treatment and therapeutics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementGZ was funded by the National Science and Technology Major Project for Control and Prevention of Major Infectious Diseases of China (No. 2017ZX10103004). CH, PZ, CY, BS, TW, JC, TM were funded by the Emergency Response Program of Harbin Institute of Technology (HITERP010) and Emergency Response Program of Peng Cheng Laboratory (PCLERP001). JL and QB were funded by a grant from the US Centers for Disease Control and Prevention (NU2GGH002000).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of the study are not publicly available. Summary data may be available from the authors upon reasonable request with permission from Shenzhen Third People's Hospital.